查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1579371

神經性厭食症市場：按治療類型、年齡層、嚴重程度、最終用戶、治療管道 - 2025-2030 年全球預測

Anorexia Nervosa Market by Treatment Type (Nutritional Counseling, Pharmacotherapy, Psychotherapy), Age Group (Adults, Children & Adolescents), Severity Level, End User, Treatment Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年神經性厭食症市值為9,465萬美元，預計2024年將達到1.0687億美元，複合年成長率為13.27%，到2030年將達到2.2652億美元。

神經性厭食症是一種嚴重的飲食障礙，其特徵是對體重增加的強烈恐懼和扭曲的身體形象，導致飲食限制和過度減肥。解決神經性厭食症的必要性源自於其嚴重的健康影響，包括營養不良、心臟問題，甚至死亡。該領域的市場研究應用包括了解患者人口統計、醫療保健方法和治療方式，最終用途範圍包括醫療保健提供者、心理健康專業人員和藥物。關鍵的成長要素是對心理健康問題的認知提高、治療性介入的進步以及對醫療保健法規的支持。潛在的商機在於擴展用於遠端患者監護的遠距遠端醫療服務、有效劑量的藥物開發以及使用人工智慧和資料分析的個人化治療計劃。然而，市場成長面臨許多限制，例如心理健康的社會恥辱、治療成本高昂以及缺乏訓練有素的專業人員等。物流限制和監管障礙使市場動態更加複雜。

主要市場統計
基準年[2023] 9465萬美元
預測年份 [2024] 10687萬美元
預測年份 [2030] 22652萬美元
複合年成長率（%） 13.27%

為了利用這些機會，公司正在創新數位健康平台以提供持續的支持和治療，探索非傳統的整體治療方法，例如正念和營養精神病學，我們應該專注於與健康倡導團體合作。此外，行動醫療技術可以針對年輕人進行早期療育和提高意識。市場的本質是動態的、競爭性的，並且要求全面且易於獲得的治療解決方案。企業應加強對影響神經性厭食症的遺傳因素的研究，這將大大促進個人化醫療。與高科技公司建立策略夥伴關係，開發穿戴式科技等先進診斷工具，可提供即時健康監測，進而改善患者的治療效果和參與度。總體而言，堅實的市場策略和先進技術的結合可以為抓住市場機會和克服現有挑戰做出重大貢獻。

市場動態：快速發展的神經性厭食症市場的關鍵市場洞察

供需的動態交互作用正在改變神經性厭食症市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 擴大線上和數位療法在治療神經性厭食症患者中的作用
    • 政府對心理健康研究和治療計劃的承諾和資助
    • 整合營養師、心理學家和醫生等多學科方法，為患者照護
  • 市場限制因素
    • 對神經性厭食症的高度恥辱和缺乏認知阻礙了早期診斷和早期療育
  • 市場機會
    • 利用人工智慧改善神經性厭食症的早期檢測與診斷
    • 制定有針對性的營養計劃以支持神經性厭食症患者的康復
  • 市場挑戰
    • 神經性厭食症的有效治療方案有限阻礙了廣泛康復

波特的五力：駕馭神經性厭食症市場的策略工具

波特的五力框架是了解神經性厭食症市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解神經性厭食症市場的外部影響

外部宏觀環境因素在塑造神經性厭食症市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解神經性厭食症市場的競爭格局

對神經性厭食症市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣神經性厭食症市場供應商的績效評估

FPNV定位矩陣是評估神經性厭食症市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製神經性厭食症市場的成功之路

對於想要加強在全球市場的影響力的公司來說，對神經性厭食症市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 線上和數位療法在神經性厭食症患者治療中的作用不斷擴大
      • 政府對心理健康研究和治療計劃的承諾和資助
      • 整合營養師、心理學家和醫生等多學科方法，提供全面的患者照護
    • 抑制因素
      • 對神經性厭食症的高度恥辱和缺乏認知阻礙了早期診斷和干涉
    • 機會
      • 利用人工智慧改善神經性厭食症的早期檢測與診斷
      • 制定有針對性的營養計劃以支持神經性厭食症患者的康復
    • 任務
      • 神經性厭食症的有效治療方案有限，阻礙了廣泛的復原。
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章神經性厭食症市場治療類型

  • 營養諮詢
  • 藥物治療
    • 抗憂鬱症
    • 抗精神病藥
    • 情緒穩定劑
  • 心理治療
    • 認知行為療法
    • 家庭治療
    • 人際心理治療

第7章神經性厭食症市場：依年齡層

  • 成人
  • 兒童和青少年

第 8 章以嚴重程度分類的神經性厭食症市場

  • 溫和的
  • 適度
  • 嚴重

第 9 章 神經性厭食症市場：依最終使用者分類

  • 診所
  • 居家護理
  • 醫院

第10章 神經性厭食症市場治療管道

  • 住院病人
  • 門診病人

第11章美洲神經性厭食症市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太神經性厭食症市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東與非洲神經性厭食症市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 一項耗資 270 萬歐元的新研究舉措旨在調查飲食障礙、自殘和自閉症之間的聯繫，並改善年輕人的早期診斷和介入。
    • Equip 獲得額外資金以擴大虛擬飲食障礙治療服務
    • 加州大學聖地牙哥分校已捐贈 235,000 美元開始一項臨床試驗，以測試酮療法預防復發的有效性。
  • 戰略分析和建議
    • 默克公司

公司名單

  • Alkermes plc
  • Amgen Inc.
  • Biohaven Pharmaceuticals
  • Hologic, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mindstrong Health
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • PsychoGenics Inc.
  • Sanofi SA
  • Sumitomo Pharma America, Inc.
  • Takeda Pharmaceutical Company Limited.
  • Tonix Pharmaceuticals Holding Corp.
Product Code: MRR-1A1A064C0422

The Anorexia Nervosa Market was valued at USD 94.65 million in 2023, expected to reach USD 106.87 million in 2024, and is projected to grow at a CAGR of 13.27%, to USD 226.52 million by 2030.

Anorexia Nervosa is a severe eating disorder characterized by an intense fear of gaining weight and a distorted body image, leading to restricted food intake and excessive weight loss. The necessity of addressing Anorexia Nervosa arises from its serious health implications, including malnutrition, heart issues, and even mortality. Application of market research in this domain includes understanding patient demographics, healthcare approaches, and treatment methodologies, while the end-use scope involves healthcare providers, mental health professionals, and pharmaceuticals. Key growth factors are the increasing awareness of mental health issues, advancements in therapeutic interventions, and supportive healthcare regulations. The potential opportunities lie in expanding telemedicine services for remote patient monitoring, pharmaceutical developments in effective medication, and personalized treatment plans leveraging AI and data analytics. However, the market growth faces limitations such as social stigma attached to mental health, high treatment costs, and a shortage of trained professionals. Logistical limitations and regulatory hurdles further complicate market dynamics.

KEY MARKET STATISTICS
Base Year [2023] USD 94.65 million
Estimated Year [2024] USD 106.87 million
Forecast Year [2030] USD 226.52 million
CAGR (%) 13.27%

To tap into these opportunities, businesses should focus on innovations in digital health platforms for continuous support and therapy, research into non-traditional and holistic treatment approaches like mindfulness and nutritional psychiatry, and collaborations with mental health advocacy groups. Additionally, mobile health technologies can target early-stage intervention and awareness among younger populations. The nature of the market is dynamic, with increasing competition and the need for comprehensive and accessible treatment solutions. Companies should enhance research on genetic factors impacting Anorexia Nervosa, contributing significantly to personalized medicine. Developing strategic partnerships with tech firms for advanced diagnostic tools like wearable technology can offer real-time health monitoring, thereby improving patient outcomes and engagement. Overall, integrating robust market strategies with advanced technology could significantly contribute to capturing market opportunities and overcoming existing challenges.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anorexia Nervosa Market

The Anorexia Nervosa Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Expanding role of online and digital therapies in treating patients with Anorexia Nervosa
    • Government initiatives and funding for mental health research and treatment programs
    • Integration of multidisciplinary approaches involving nutritionists, psychologists, and medical doctors for comprehensive patient care
  • Market Restraints
    • High stigma and lack of awareness surrounding anorexia nervosa impede early diagnosis and intervention
  • Market Opportunities
    • Leveraging artificial intelligence to improve early detection and diagnosis of anorexia nervosa
    • Developing targeted nutritional programs to support recovery in anorexia nervosa patients
  • Market Challenges
    • Limited effective treatment options for anorexia nervosa hinder widespread recovery

Porter's Five Forces: A Strategic Tool for Navigating the Anorexia Nervosa Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anorexia Nervosa Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anorexia Nervosa Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anorexia Nervosa Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anorexia Nervosa Market

A detailed market share analysis in the Anorexia Nervosa Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anorexia Nervosa Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anorexia Nervosa Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anorexia Nervosa Market

A strategic analysis of the Anorexia Nervosa Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anorexia Nervosa Market, highlighting leading vendors and their innovative profiles. These include Alkermes plc, Amgen Inc., Biohaven Pharmaceuticals, Hologic, Inc., Johnson & Johnson, Merck & Co., Inc., Mindstrong Health, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., PsychoGenics Inc., Sanofi S.A., Sumitomo Pharma America, Inc., Takeda Pharmaceutical Company Limited., and Tonix Pharmaceuticals Holding Corp..

Market Segmentation & Coverage

This research report categorizes the Anorexia Nervosa Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Nutritional Counseling, Pharmacotherapy, and Psychotherapy. The Pharmacotherapy is further studied across Antidepressants, Antipsychotics, and Mood Stabilizers. The Psychotherapy is further studied across Cognitive Behavioral Therapy, Family-Based Therapy, and Interpersonal Psychotherapy.
  • Based on Age Group, market is studied across Adults and Children & Adolescents.
  • Based on Severity Level, market is studied across Mild, Moderate, and Severe.
  • Based on End User, market is studied across Clinics, Homecare, and Hospitals.
  • Based on Treatment Channel, market is studied across In-Patient and Out-Patient.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Expanding role of online and digital therapies in treating patients with Anorexia Nervosa
      • 5.1.1.2. Government initiatives and funding for mental health research and treatment programs
      • 5.1.1.3. Integration of multidisciplinary approaches involving nutritionists, psychologists, and medical doctors for comprehensive patient care
    • 5.1.2. Restraints
      • 5.1.2.1. High stigma and lack of awareness surrounding anorexia nervosa impede early diagnosis and intervention
    • 5.1.3. Opportunities
      • 5.1.3.1. Leveraging artificial intelligence to improve early detection and diagnosis of anorexia nervosa
      • 5.1.3.2. Developing targeted nutritional programs to support recovery in anorexia nervosa patients
    • 5.1.4. Challenges
      • 5.1.4.1. Limited effective treatment options for anorexia nervosa hinder widespread recovery
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anorexia Nervosa Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Nutritional Counseling
  • 6.3. Pharmacotherapy
    • 6.3.1. Antidepressants
    • 6.3.2. Antipsychotics
    • 6.3.3. Mood Stabilizers
  • 6.4. Psychotherapy
    • 6.4.1. Cognitive Behavioral Therapy
    • 6.4.2. Family-Based Therapy
    • 6.4.3. Interpersonal Psychotherapy

7. Anorexia Nervosa Market, by Age Group

  • 7.1. Introduction
  • 7.2. Adults
  • 7.3. Children & Adolescents

8. Anorexia Nervosa Market, by Severity Level

  • 8.1. Introduction
  • 8.2. Mild
  • 8.3. Moderate
  • 8.4. Severe

9. Anorexia Nervosa Market, by End User

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Homecare
  • 9.4. Hospitals

10. Anorexia Nervosa Market, by Treatment Channel

  • 10.1. Introduction
  • 10.2. In-Patient
  • 10.3. Out-Patient

11. Americas Anorexia Nervosa Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Anorexia Nervosa Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Anorexia Nervosa Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. A new EUR 2.7 million research initiative explores eating disorders, self-harm, and autism links to improve early diagnosis and interventions among youth
    • 14.3.2. Equip secures additional funding to expand virtual eating disorder treatment services
    • 14.3.3. UC San Diego launches clinical trial with USD 235,000 donation to explore ketogenic therapy effectiveness on anorexia nervosa relapse prevention
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. Merck & Co., Inc.

Companies Mentioned

  • 1. Alkermes plc
  • 2. Amgen Inc.
  • 3. Biohaven Pharmaceuticals
  • 4. Hologic, Inc.
  • 5. Johnson & Johnson
  • 6. Merck & Co., Inc.
  • 7. Mindstrong Health
  • 8. Otsuka Pharmaceutical Co., Ltd.
  • 9. Pfizer Inc.
  • 10. PsychoGenics Inc.
  • 11. Sanofi S.A.
  • 12. Sumitomo Pharma America, Inc.
  • 13. Takeda Pharmaceutical Company Limited.
  • 14. Tonix Pharmaceuticals Holding Corp.

LIST OF FIGURES

  • FIGURE 1. ANOREXIA NERVOSA MARKET RESEARCH PROCESS
  • FIGURE 2. ANOREXIA NERVOSA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANOREXIA NERVOSA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ANOREXIA NERVOSA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ANOREXIA NERVOSA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANOREXIA NERVOSA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANOREXIA NERVOSA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANOREXIA NERVOSA MARKET DYNAMICS
  • TABLE 7. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ANTIPSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY MOOD STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY-BASED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL PSYCHOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN & ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY IN-PATIENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY OUT-PATIENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. CHINA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. CHINA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. CHINA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. INDIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. INDIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 108. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 122. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 129. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 136. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 150. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 157. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 164. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 177. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 179. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 186. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 193. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 198. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 200. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 205. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 207. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 214. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. ITALY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. ITALY ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 221. ITALY ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 226. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 228. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 233. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 235. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 240. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 242. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 247. POLAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. POLAND ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 249. POLAND ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 254. QATAR ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. QATAR ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 256. QATAR ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 261. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 263. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 268. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 270. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 275. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 277. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 282. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 284. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 289. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 291. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 292. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 296. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 298. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 299. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 303. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 304. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 305. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 306. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 310. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 312. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 313. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 324. ANOREXIA NERVOSA MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 325. ANOREXIA NERVOSA MARKET, FPNV POSITIONING MATRIX, 2023